Overview
Whether you arrived from a “Injective vs SMILEK” query or from PEPS coin pages, this hub aggregates ranks, performance and module-backed signals into one canonical URL.
Quick winners
Full comparison
| Metric | INJ | SMILEK |
|---|---|---|
| Price | $5.13 | $1,882.43 |
| Market Cap | $490.41M | $87.41M |
| FDV | — | — |
| Volume 24h | $2.59M | $787.02 |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 280.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | SMILEK |
|---|---|---|
| 1H | — | — |
| 24H | +3.91% | +0.00% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | SMILEK |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.47 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 59.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Use the indicator table as a checklist: if momentum and trend align on one asset while the other diverges, relative-value setups become more interesting — still without certainty.
Fundamentals
| Metric | INJ | SMILEK |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
SMILEK
Pros and cons
Pros of Injective
- Higher ranking for Injective can translate into tighter spreads on major venues.
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
- INJ often anchors narratives that attract sustained media and analyst coverage.
Cons of Injective
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
- When dominance narratives fade, Injective can lag hotter rotation names.
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
Pros of SMILEK
- Narrative optionality around SMILEK can reprice quickly when catalysts appear.
- Active volume bursts on SMILEK sometimes precede sharper tactical moves.
- SMILEK can offer higher relative beta when market attention rotates toward its niche.
Cons of SMILEK
- Trend failures on SMILEK often travel faster than on more established assets.
- Weaker market-cap standing may leave SMILEK more exposed to liquidity droughts.
- Relative underperformance versus Injective can persist through entire market regimes.
- Smaller book depth versus large caps can increase slippage for SMILEK.
Which looks stronger right now?
Statistically, higher market cap (Injective) often correlates with deeper books, while hotter 24h prints (Injective) can fade. Position sizing should reflect that uncertainty.
AI summary
In about three hundred words of context: Injective (INJ) trades near $5.13 with a +3.91% day move, while SMILEK (SMILEK) is around $1,882.43 (+0.00%). Volume leadership currently sits with Injective, and market-cap leadership with Injective. Technical trend labels read neutral vs bearish, with RSI near 49.29/49.02. Bottom line: use this page as a structured checklist, then open each coin page and related PEPS tools before acting. Nothing here is financial advice.
FAQ
Which is better, Injective or SMILEK?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or SMILEK?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and SMILEK.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.